US 10500277
Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma
granted A61KA61K31/704A61K35/74
Quick answer
US patent 10500277 (Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma) held by EnGeneIC Molecular Delivery Pty Ltd expires Mon Dec 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- EnGeneIC Molecular Delivery Pty Ltd
- Grant date
- Tue Dec 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 22
- CPC classes
- A61K, A61K31/704, A61K35/74, A61K38/217, A61K39/3955